Literature DB >> 10840195

Cellular delivery of antisense oligonucleotides.

I Lebedeva1, L Benimetskaya, C A Stein, M Vilenchik.   

Abstract

Antisense oligonucleotides can be successfully employed to inhibit specifically gene expression. However, many oligonucleotide classes are polyanions and cannot passively transit the cell membrane. Thus, the use of naked oligonucleotides for antisense purposes poses some rather stringent challenges, and it is not a trivial task to appropriately interpret the data derived from experiments in which they have been used. Multiple methods have been developed to improve intracellular, and in particular, intranuclear oligonucleotide delivery, and in doing so, to maximize the performance of the antisense technologies that are currently available. This review discusses the use of cationic lipids, protein and peptide delivery agents, and several novel chemical and viral methods that have recently been explored as delivery vehicles, focussing not only on their strengths, but also on their limitations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840195     DOI: 10.1016/s0939-6411(00)00088-6

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  24 in total

Review 1.  Strategies for identifying genes that play a role in spinal cord regeneration.

Authors:  M Wintzer; M Mladinic; D Lazarevic; C Casseler; A Cattaneo; J Nicholls
Journal:  J Anat       Date:  2004-01       Impact factor: 2.610

2.  Uptake and antifungal activity of oligonucleotides in Candida albicans.

Authors:  Matthew D Disney; Constantine G Haidaris; Douglas H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

Review 3.  Improvement of DNA transfection with cationic liposomes.

Authors:  A Rocha; S Ruiz; J M Coll
Journal:  J Physiol Biochem       Date:  2002-03       Impact factor: 4.158

Review 4.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

5.  In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotides.

Authors:  Elisabeth von Guggenberg; Soraya Shahhosseini; Ingrid Koslowsky; Afsaneh Lavasanifar; David Murray; John Mercer
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

6.  Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.

Authors:  Ying Wang; Lu Huang; Yunmei Yang; Liqian Xu; Ji Yang; Yue Wu
Journal:  Mol Biol Rep       Date:  2013-03-04       Impact factor: 2.316

Review 7.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

8.  Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides.

Authors:  María González Ferreiro; Lloyd G Tillman; Gregory Hardee; Roland Bodmeier
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates.

Authors:  Takehiko Shiraishi; Peter E Nielsen
Journal:  Nucleic Acids Res       Date:  2004-09-15       Impact factor: 16.971

10.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.